Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 26Lymphoma, Non-Hodgkin 22Lymphoma 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 14Lymphoma, Follicular 13Recurrence 12Waldenstrom Macroglobulinemia 9Neoplasms 8Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphoid 6Leukemia, B-Cell 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Myeloid, Acute 3Leukemia 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Neoplasms 3Hematologic Diseases 2Burkitt Lymphoma 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1

Interventions

Rosuvastatin Calcium 5capivasertib 2Digoxin 2sotorasib 1ibrutinib 1Midazolam 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Healthy Participants × ibrutinib × Clear all
NCT01674322 2014-11-05

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Janssen Research & Development, LLC

Phase 1 Completed
6 enrolled

Healthy Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡